Efficacy of CB1R inverse agonists for enhancing insulin secretion in mouse and human islets, ex vivo, and for preventing cytokine-induced ?-cell death in human islets

Inversago and CR-CHUM will collaborate to evaluate new generation Cannabinoid-1 receptor (CB1) blockers for the treatment and/or prevention of type-1 and type-2 diabetes. Previous generations of CB1 blockers have shown their promise in treating several features of the metabolic syndrome, including obesity, type-2 diabetes and liver diseases. However, they were plagued with important psychiatric adverse […]

Read More